(Press-News.org) Results from a 12-month multi-center clinical trial did not show therapeutic benefit of abatacept over placebo in patients with non-life threatening systemic lupus erythematosus (SLE). Abatacept failed to prevent new disease flares in SLE patients tapered from corticosteroids in an analysis where mild, moderate and severe disease flares were evaluated together. Full details of the phase IIb clinical trial are published in the October issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR).
The ACR estimates that 161,000 to 322,000 adults in the U.S. have SLE, an autoimmune disease that can affect multiple systems in the body. Those with SLE may experience periods of increased disease activity (flares). Manifestations of lupus range from mild, single-organ involvement to more severe involving multiple organs, which can also lead to organ failure. Treatments for SLE include the off-label clinical use of immunosuppressives such as azathioprine, methotrexate, and cyclophosphamide, which may still require the use of high-dose corticosteroids. Corticosteroids, such as prednisone, are effective in treating flares, but are associated with toxicities and long-term use place patients at risk for severe comorbidities.
Prior studies have shown that abatacept is safe and effective in patients with rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA). The Food and Drug Administration (FDA) and European Medicines Agency (EMA) currently approve abatacept for the treatment of moderate to severe RA and JIA, leading researchers to believe it may be an appropriate therapy for other autoimmune diseases such as SLE. "Corticosteroids have serious side effects, so treatments that are targeted and could control disease activity while allowing steroid tapering would represent an advance in lupus therapy," said lead author of the current study, Joan T. Merrill, M.D. of the Oklahoma Medical Research Foundation.
Dr. Merrill and colleagues conducted the first trial to assess the effects of abatacept on disease flares in patients with non-life threatening SLE. There were 175 patients included in the trial whose primary symptoms included active polyarthritis, chronic discoid skin lesions, pleuritis, and/or pericarditis. Participants were randomized with 118 administered abatacept (10mg/kg of body weight) by intravenous (IV) infusion on days 1, 15, 29 and every 4 weeks throughout the 12-month period. There were 57 patients in the placebo group who received normal saline IV infusion. Prednisone (30 mg/day) was administered to both groups for 1 month and then tapered.
At the completion of the study 68.6% of participants remained in the abatacept group and 61.4% in the placebo group. Researchers found the most frequent reason for discontinuation was lack of efficacy—17.8% in the abatacept group and 21.1% in the placebo cohort. Further more, the proportion of patients with a new flare following the steroid taper was 79.7% and 82.5% in the abatacept and placebo groups, respectively. In ad hoc analyses, there were greater differences when severe flares or physician-reported flares were analyzed separately, and in the subset of patients who entered the study with active arthritis, but these findings are considered exploratory and would require confirmation in future studies.
The research team also found that the frequency of patients with serious adverse events (SAEs) was higher in participants receiving abatacept (19.8%) than with those in the placebo group (6.8%). SAEs were single events ranging from nausea to lupus nephritis, and most often occurred during the first 6 months of the study, including the 2-month steroid taper period. Researchers suggest that the majority of SAEs could be attributed to SLE disease activity.
This trial demonstrated that the combination of abatacept, background treatments, and forced steroid taper poses an unacceptable safety risk to SLE patients. "While there is potential for clinical application of abatacept, further studies are needed to evaluate whether there are subsets of patients for whom this treatment might be useful, and then to determine the best way to treat and monitor such patients," concluded Dr. Merrill.
INFORMATION:
Article: "The Efficacy and Safety of Abatacept in Patients with Non–Life Threatening Manifestations of Systemic Lupus Erythematosus." J. T. Merrill, R. Burgos-Vargas, R. Westhovens, A. Chalmers, D. D'Cruz, D. J. Wallace, S. C. Bae, L. Sigal, J.-C. Becker, S. Kelly, K. Raghupathi, T. Li, Y. Peng, M. Kinaszczuk, and P. Nash. Arthritis & Rheumatism; Published Online: June 8, 2010 (DOI: 10.1002/art.27601); Print Issue Date: October 2010. http://onlinelibrary.wiley.com/doi/10.1002/art.27601/abstract
This study is published in Arthritis & Rheumatism. Media wishing to receive a PDF of the article may contact healthnews@wiley.com.
Arthritis & Rheumatism is an official journal of the American College of Rheumatology and covers all aspects of inflammatory disease. The American College of Rheumatology (www.rheumatology.org) is the professional organization who share a dedication to healing, preventing disability, and curing the more than 100 types of arthritis and related disabling and sometimes fatal disorders of the joints, muscles, and bones. Members include practicing physicians, research scientists, nurses, physical and occupational therapists, psychologists, and social workers. For details please visit, http://www3.interscience.wiley.com/journal/76509746/home.
About Wiley-Blackwell
Wiley-Blackwell is the international scientific, technical, medical, and scholarly publishing business of John Wiley & Sons, with strengths in every major academic and professional field and partnerships with many of the world's leading societies. Wiley-Blackwell publishes nearly 1,500 peer-reviewed journals and 1,500+ new books annually in print and online, as well as databases, major reference works and laboratory protocols. For more information, please visit www.wileyblackwell.com or our new online platform, Wiley Online Library (wileyonlinelibrary.com), one of the world's most extensive multidisciplinary collections of online resources, covering life, health, social and physical sciences, and humanities.
END
The Structural Genomics Consortium (SGC), an international public-private partnership that aims to determine three dimensional structures of medically important proteins, announced today the release into the public domain of its 1000th high resolution protein structure.
The 1000th structure – known as JmjD2C – belongs to a class of proteins involved in epigenetic signalling, a key research area for the SGC. Epigenetics is the study of inherited changes in gene expression caused by proteins such as JmjD2C which 'switch' genes on or off. It is believed that a better understanding ...
HOUSTON, Sept. 28, 2010 – A large section of northwestern Harris County – particularly the Jersey Village area – is sinking rapidly, according to a University of Houston (UH) geologist who has analyzed GPS data measuring ground elevation in the Houston area.
Some points in Jersey Village are subsiding by up to 5.5 centimeters (about 2 inches) a year, said Shuhab Khan, an associate professor of geology at UH. Khan, along with UH geology professor Kevin Burke and former Ph.D. student and UH alumnus Richard Engelkemeir, studied a decade's worth of detailed GPS data measuring ...
In comments sent to Secretary Kathleen Sebelius at the U.S. Department of Health and Human Services, AMIA (American Medical Informatics Association) called out 10 specific challenges to proposed modifications to HIPAA Privacy and Enforcement Rules. AMIA's comments, sent on behalf of its membership of 4,000 informatics professionals, detail key issues of concern related to the Notice of Proposed Rulemaking (NPRM) on HIPAA modifications, along with suggestions for models of change. The following areas were cited:
Business Associates and Subcontractors
Position: AMIA ...
Although the magnificent frigatebird may be the least likely animal on the Galapagos Islands to be unique to the area, it turns out the Galapagos population of this tropical seabird may be its own genetically distinct species warranting a new conservation status, according to a paper by researchers at the Smithsonian Conservation Biology Institute, the Smithsonian's National Museum of Natural History and the University of Missouri-St. Louis published last week in the scientific journal Proceedings of the Royal Society B.
The Galapagos Islands, which once served as a scientific ...
When the scientific and spiritual worlds collide, they do so in the most surprising ways. Classical meteorological and plant science has, in the last century, insisted that dew negatively affects plant life, leading to rot and fungus. But in the Judeo-Christian tradition, dew is most welcomed as an important source of vegetative and plant life, celebrated in poetry and prayer.
Now Prof. Pinhas Alpert of Tel Aviv University's Department of Geophysics and Planetary Sciences has developed an explanation for the perplexing paradox with his colleagues. According to scientific ...
A study carried out by Spanish researchers has shown that the presence of chemical contaminants can interact with noise and modify, for good or for bad, the way in which work-related "deafness" – which is increasingly common among young people – manifests itself. Noise-related hearing loss is the most common occupational disease in Europe.
"Workers exposed to noise in the presence of metalworking fluids exhibit a delay in hearing alteration in comparison with those exposed only to noise at the same intensity. However, those exposed to noise in the presence of welding ...
Astroturfers, Twitter-bombers and smear campaigners need beware this election season as a group of leading Indiana University information and computer scientists today unleashed Truthy.indiana.edu, a sophisticated new Twitter-based research tool that combines data mining, social network analysis and crowdsourcing to uncover deceptive tactics and misinformation leading up to the Nov. 2 elections.
Combing through thousands of tweets per hour in search of political keywords, the team based out of IU's School of Informatics and Computing will isolate patterns of interest ...
FORT WORTH, TEXAS, USA, September 28, 2010—The outbreak of whooping cough in Texas, California, and other states this year underscores the critical importance of widespread vaccination coverage, both locally as well as around the world, said a leading global health official attending conferences on world affairs and immunization in Fort Worth this week.
Alex Palacios, a special representative of the GAVI Alliance, a public-private partnership aimed at increasing immunisation rates in poor countries, said that despite public health advances in the US and other wealthy countries ...
More than half of all people are hosts to Candida albicans in their bodies. This species might be located on their skin or mucous membranes or in the intestines – frequently without causing any symptoms. However, it can be dangerous to patients whose immunological system has been weakened such as after organ transplants or chemotherapy with cancer. Then, this fungus penetrates into deeper layers of tissue and uses the blood system to spread throughout the body. In Germany alone, several thousand people die from systemic candida infections every year.
But why does Candida ...
Sept. 28, 2010 -- A new report from the National Research Council says that more organized and systematic procedures for gathering and evaluating data on Missouri River sediment are required to improve decisions and better manage the river's ecosystem, including protecting endangered species and developing water quality standards. In addition, the report finds that the U.S. Army Corps of Engineers' projects to restore habitats along the Missouri River are not significantly changing the size of the oxygen-depleted "dead zone" in the Gulf of Mexico, nor will options for ...
